Repare Therapeutics

Repare Therapeutics presented updated data at EORTC-NCI-AACR Symposium showing benefits of individualized anemia management in Phase 1 MYTHIC trial with lunresertib and camonsertib, reducing Grade 3 anemia and maintaining clinical benefit.

Repare Therapeutics announced the first patient dosed in its Phase 1 POLAR trial evaluating RP-3467, a Polθ ATPase inhibitor, alone and with olaparib, aiming to improve patient outcomes by mitigating PARP inhibitor resistance.

Repare Therapeutics has initiated its Phase I POLAR trial of RP-3467, a Polθ ATPase inhibitor, for treating various solid tumours. The open-label, multicentre trial aims to evaluate RP-3467's safety, pharmacokinetics, and clinical activity, either alone or with olaparib. The study will enroll 52 adults with advanced solid tumours, focusing on safety and tolerability, and will determine a recommended Phase II dose for RP-3467 in combination with olaparib.

Repare Therapeutics reported clinical benefits of camonsertib, an ATR inhibitor, combined with palliative radiation for metastatic tumors with ATM mutations, presented at ASTRO annual meeting. The study enrolled 17 patients, showing potential radiosensitization and higher clinical benefit in those with pathogenic ATM mutations.

S.K., D.A.M., J.P., H.S., X.Z., P.H., T.X., and H.S. have financial ties to various pharmaceutical companies, including stock ownership and advisory roles. F.C., J.D., E.V.C., H.S.W., T.Y., R.Y., and J.T. also report consulting or advisory roles and research funding from multiple institutions and companies.

Ovarian and endometrial cancers with CCNE1 amplifications, FBXW7 or PP2R1A mutations have poor prognosis, according to data from AACR's Ovarian Cancer Research Symposium. Patients with these biomarkers show significantly lower survival rates, highlighting the need for innovative therapies.